437 related articles for article (PubMed ID: 30342533)
1. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
2. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
4. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
[TBL] [Abstract][Full Text] [Related]
5. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
6. Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
Li Z; Peng Z; Gu S; Zheng J; Feng D; Qin Q; He J
Anticancer Res; 2017 Aug; 37(8):4455-4468. PubMed ID: 28739740
[TBL] [Abstract][Full Text] [Related]
7. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.
Xiao B; Zhang W; Chen L; Hang J; Wang L; Zhang R; Liao Y; Chen J; Ma Q; Sun Z; Li L
Gene; 2018 Jun; 658():28-35. PubMed ID: 29518546
[TBL] [Abstract][Full Text] [Related]
9. Expression of micrornas in molecular genetic breast cancer subtypes.
Kolesnikov NN; Veryaskina YA; Titov SE; Rodionov VV; Gening TP; Abakumova TV; Kometova VV; Torosyan MK; Zhimulev IF
Cancer Treat Res Commun; 2019; 20():100026. PubMed ID: 31255253
[TBL] [Abstract][Full Text] [Related]
10. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
11. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
Sharma P; Saraya A; Sharma R
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e289-e301. PubMed ID: 29380534
[TBL] [Abstract][Full Text] [Related]
12. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
13. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
[TBL] [Abstract][Full Text] [Related]
14. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
17. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
[TBL] [Abstract][Full Text] [Related]
18. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
19. Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value.
Fahim SA; Abdullah MS; Espinoza-Sánchez NA; Hassan H; Ibrahim AM; Ahmed SH; Shakir G; Badawy MA; Zakhary NI; Greve B; El-Shinawi M; Götte M; Ibrahim SA
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708601
[TBL] [Abstract][Full Text] [Related]
20. A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases.
Xiong DD; Lv J; Wei KL; Feng ZB; Chen JT; Liu KC; Chen G; Luo DZ
Oncol Rep; 2017 Jun; 37(6):3297-3304. PubMed ID: 28440475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
